权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanistic characterization of the cell cycle-dependent DNA repair pathway- Resubmission

细胞周期依赖性 DNA 修复途径的机制表征 - Resubmission

基本信息

批准号：
10579880
负责人：
Justin Wai Chung Leung
金额：
$ 23.99万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2027-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10579880
关键词：
BARD1 gene BRCA1 gene Binding Binding Proteins Biochemical Biological Biological Assay Cell Cycle Cell Cycle Regulation Cell Line Cell physiology Cells Choices and Control Chromatin Complex Cytoprotection DNA DNA Damage DNA Double Strand Break DNA Repair DNA Repair Gene DNA Repair Pathway Defect Development Docking Double Strand Break Repair Drug Targeting Ensure Epigenetic Process G1 Phase Genetic Genetic Materials Genetic study Genome Genomic Instability Goals Histones Inherited Kinetics Knock-out Knowledge Maintenance Malignant - descriptor Malignant Neoplasms Mediating Mental Retardation Methylation Modeling Molecular Mutagens Mutation Nonhomologous DNA End Joining Pathway interactions Peptides Proteins Proteomics Radiation Radiation therapy Reader Recombinants Regulation Reporter Role Scaffolding Protein Shapes Site Tail Testing Therapeutic Therapeutic Agents Time Translating Work Zinc Fingers biomarker discovery cancer cell cancer therapy chromatin modification drug discovery epigenome genome integrity histone modification homologous recombination innovation insight neoplastic cell novel therapeutic intervention p53-binding protein 1 potential biomarker prevent protective pathway proteostasis recombinational repair recruit repaired response spatiotemporal tumor

项目摘要

PROJECT SUMMARY Chromatin-based DNA damage response (DDR) pathway is fundamental for protecting cells from genome instability, which is a hallmark of cancer. The DDR pathway is tightly regulated throughout the cell cycle to ensure spatiotemporal control of DNA repair. Cell cycle-regulated chromatin modification is crucial for orchestrating DNA repair. Notably, H4K20 methylation is a cell cycle-dependent histone mark that is involved in DNA double-strand break (DSB) repair pathway choice. Newly incorporated unmodified H4 recruits TONSL to replicated damaged chromatin to execute homologous recombination (HR) repair; whereas, H4K20me2 recruits 53BP1 to damaged chromatin predominately at G1 phase to promote non-homologous end joining (NHEJ). The knowledge gap for the current model comes from the unclear role and regulation of H4K20me1 and DSB repair pathway choice. Identifying histone H4K20me readers provides important insights into how chromatin modifications execute cellular functions by recruiting downstream effector proteins to damaged chromatin at the right time. We identified ZMYM3 (Zinc finger myeloproliferative and mental retardation, type-3), as an HR promoting factor, which specifically binds to the H4K20 methylation mark. The overall objective of this project is to elucidate the mechanistic regulatory role of ZMYM3 on cell cycle-regulated H4K20 methylation, and how it translates into DNA DSBs repair pathway choice on post-replicative chromatin. Specifically, we propose to 1) determine the connection between ZMYM3 and H4K20 methylation by biochemical assays and genetic studies; 2) characterize the ZMYM3 functional complex(es) on post-replicative damaged chromatin; and 3) elucidate the mechanism of how ZMYM3 regulates cell cycle-regulated DSB repair pathway choice and. We will focus on investigating DYNLL1/LC8, a recently characterized DNA repair protein, and its physical, genetic and functional connections with ZMYM3 in DSB repair regulation. Our long-term goal is to dissect the detail of how cells orchestrate DNA repair via chromatin modifications. These studies are poised to provide critical insights into how H4K20me1 and H4K20me2 dictate the choice between HR and NHEJ on post-replicative chromatin repair. It will also decipher how ZMYM3 shapes the post-replicative chromatin epigenome and recruits DDR proteins at damaged chromatin. Although inherited DDR defects predispose in cancer development, the vulnerability is therapeutically exploited to preferentially kill tumor cells. Thus, DNA damaging agents are a major class of therapeutic agents that include radiotherapy. Since chromatin directly regulates DNA repair proteins accrual at damaged chromatin, the epigenome is an attractive target for drug discovery for cancer treatment. This work exploits a combination of biochemical, genetic, epigenetics and cellular approaches to dissect the detailed mechanism of cell cycle- regulated epigenome on genome integrity maintenance that can translate to potential biomarkers and drug discovery for cancer treatment.

项目总结